=Sarepta Therapeutics (SRPT) reported earnings on Wed 19 July 2017 (a/h)

Sarepta Therapeutics (SRPT) stock bolted late Wednesday after the biotech smashed Wall Street views for second-quarter sales and reported narrowing losses just a day after it settled a patent dispute with BioMarin Pharmaceuticals (BMRN).

For the second quarter ended June 30, Sarepta reported adjusted losses of 46 cents a share on revenue of $35 million, compared with losses of $1.19 per share and no revenue in the year-ago quarter. Both metrics topped the consensus for a 92-cent loss and $22 million in sales.

The biotech also boosted its 2017 guidance to $125 million to $130 million after, earlier in the day, announcing a program to expand access to its only approved drug, Exondys 51, a treatment for patients with Duchenne muscular dystrophy.

Patients in North America, South America and Europe will benefit from the program which, Leerink analyst Joseph Schwartz said earlier Wednesday, could add meaningful revenue to Sarepta's top line in 2017. Schwartz has an outperform rating on Sarepta stock.